Confo Therapeutics N.V.

https://www.confotherapeutics.com

Confo Therapeutics is a VUB-VIB spin-off co-founded in 2015 by VIB and Capricorn Venture Partners with the support of MINTS, PMV, QBIC and V-Bio Ventures. The Company is building a portfolio of first-in-class programs based on its proprietary Confo® technology which makes use of antibody fragments or “Confobodies” to stabilize G-protein coupled receptors (GPCRs) in a particular conformation of interest as a superior starting point for drug discovery. GPCRs are attractive drug targets in the treatment of many different conditions, playing an essential part in numerous life processes and influencing diseases. In addition to developing its own pipeline, Confo Therapeutics is entering into revenue-generating drug discovery partnerships with select pharma companies, on GPCR targets which do not compete with its internal projects. The Company has ongoing collaborations with Lundbeck and Roche. *

	Start	2015-06-01 established (s-off)
	Predecessor	VIB (Flanders Interuniversity Institute for Biotechnology / Vlaams Instituut voor Biotechnologie)
	Industry	drug discovery
	Industry 2	angiotensin-II receptor antagonist (AT2R inhibitor)
	Person	Ververken, Cedric (Confo Therapeutics 201610– CEO before Ablynx)

	Region	Brussels
	Country	Belgium
	Street	2 Pleinlaan Building E, 7th Floor, Room E7.6
	City	1050 Brussels
		Address record changed: 2020-12-02

Basic data	Employees	B: 11 to 50 (2017-10-26)

		* Document for »About Section«: Confo Therapeutics N.V.. (1/3/19). "Press Release: Confo Therapeutics Announces Exclusive, Worldwide License Agreement with VIB for Powerful Novel Structure Determination Technology". Ghent.

		Record changed: 2024-07-30